Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
ALSA Ventures is a London-based international life science investor established to capitalize on European innovation in biotechnology. Founded with the mission to create valuable businesses that have a global impact, ALSA Ventures focuses on companies developing novel therapeutics. The firm operates primarily in Europe and the United Kingdom, leveraging its extensive network within the life sciences sector to identify promising investment opportunities.
Currently, ALSA Ventures manages a portfolio that includes several notable biotechnology companies. The firm engages in investments across various stages, from pre-seed to growth equity, ensuring a comprehensive approach to supporting the development of innovative therapeutics. Their commitment to fostering advancements in life sciences positions them as a key player in the European biotech investment landscape.
ALSA Ventures primarily invests in the biotechnology sector, with a strong emphasis on therapeutics. The firm seeks novel drugs and modalities that address a wide variety of disease areas, including chronic inflammatory diseases and oncology. Their investment strategy encompasses the entire drug development spectrum, from company formation to syndicate participation with co-investors. This broad approach allows ALSA Ventures to engage with companies at various stages of their development, providing the necessary support to bring innovative therapeutics to market.
Geographically, ALSA Ventures focuses on opportunities within Europe and the United Kingdom. Their strong network within the biotechnology sector enables them to identify and evaluate innovative breakthroughs effectively. The firm looks for founders who demonstrate a deep understanding of their market and possess a clear vision for their therapeutic developments.
ALSA Ventures has built a diverse portfolio of biotechnology companies, each focused on developing innovative therapeutics. Notable companies include:
In addition to these key players, ALSA Ventures supports other companies working on treatments for chronic inflammatory diseases, IgE drugs for solid cancer tumors, and first-in-class oncology drugs leveraging proprietary databases. This diverse portfolio reflects the firm's commitment to advancing healthcare through innovative biotechnology solutions.
Alek Safarian - CEO: Alek has extensive experience in the life sciences sector, leading ALSA Ventures in identifying and supporting innovative biotechnology companies.
Lorna Collings - CFO: Lorna oversees the financial operations of ALSA Ventures, ensuring sound fiscal management and strategic financial planning.
Dr. Bruce Goldsmith - Operating Partner: Bruce brings a wealth of operational expertise in biotechnology, guiding portfolio companies through the complexities of drug development.
Dr. Robert Balfour - Investment Director: Robert focuses on sourcing and evaluating investment opportunities within the biotechnology sector.
Katie Sunnucks - Investment Director: Katie plays a key role in managing the investment process and supporting portfolio companies.
Andre Badalyan - Investment Associate: Andre assists in deal sourcing and due diligence for potential investments.
Julia Jones - Investment Manager: Julia manages relationships with portfolio companies and supports their growth strategies.
Dr. Graeme Martin - Venture Partner: Graeme provides strategic insights and guidance based on his extensive experience in the biotechnology field.
Laura Higgins - Accounts Assistant: Laura supports the financial operations of the firm.
Professor Jyoti Choudhary - Advisor: Jyoti offers academic insights and guidance on scientific developments in biotechnology.
Professor Gerard Evan - Advisor: Gerard provides expertise in cancer biology and therapeutic development.
What are ALSA Ventures' investment criteria?
ALSA Ventures invests in biotechnology companies that are developing novel therapeutics across various disease areas. They focus on companies at different stages, from pre-seed to growth equity, and seek innovative solutions that can have a significant impact on healthcare.
How can founders pitch to ALSA Ventures?
Founders interested in pitching to ALSA Ventures should prepare a comprehensive presentation that outlines their business model, market opportunity, and the uniqueness of their therapeutic approach. A clear understanding of the competitive landscape is also essential.
What makes ALSA Ventures different from other investors?
ALSA Ventures distinguishes itself through its strong network within the biotechnology sector, which enables them to identify and evaluate innovative breakthroughs effectively. Their focus on the entire drug development spectrum allows them to provide tailored support to portfolio companies.
What is the geographic scope of ALSA Ventures?
The firm primarily operates in Europe and the United Kingdom, focusing on biotechnology companies that are leveraging European innovation in life sciences.
What kind of post-investment involvement does ALSA Ventures have?
ALSA Ventures actively engages with its portfolio companies, providing operational support and strategic guidance to help them navigate the complexities of drug development and commercialization.
What is the typical check size for investments made by ALSA Ventures?
ALSA Ventures invests across a range of stages, including pre-seed, seed, Series A, Series B, and growth equity, with check sizes varying accordingly based on the stage and needs of the company.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.